Generics of Tecfidera not available in Europe until at least 2025
The European Commission (EC) has withdrawn its marketing authorizations for generic versions of Tecfidera (dimethyl fumarate), an oral therapy approved in Europe for relapsing-remitting multiple sclerosis (RRMS). According toĀ Biogen, which developed and markets the brand-name medication, the decision ensures Biogen will have full data and marketing protection…